| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-06-13 | BioAlliance Pharma (France) Abic Marketing Limited,a group subsidiary of Teva Pharmaceutical (Israel) | Sitavig® (Acyclovir Lauriad™) | recurrent labial herpes in immunocompetent patients | licensing |
Infectious diseases | Licensing agreement |
| 2012-06-13 | Lonza (Switzerland) Biowa (Japan) FivePrime Therapeutics (USA) | POTELLIGENT® CHOK1SV Cell Line | licensing |
Cancer - Oncology | Licensing agreement | |
| 2012-06-12 | BioInvent (Sweden) Cancer Research Technology (UK) Queen Mary, University of London (UK) | new therapeutic antibodies in oncology | cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2012-06-12 | ADVENTRX Pharmaceuticals (USA) Pierre Fabre Medicament (France) | ANX-188 (purified poloxamer 188) | production |
Hematological diseases | Production agreement | |
| 2012-06-11 | Fundación MEDINA (Spain) Cubist Pharmaceuticals (USA - MA) | novel antibiotics | infectious diseases | R&D |
Infectious diseases | R&D agreement |
| 2012-06-11 | Stiefel, a GSK company (UK) Basilea Pharmaceutica (Switzerland) | Toctino® (alitretinoin) | severe chronic hand eczema unresponsive to potent topical steroids in adults | licensing -product acquisition | Dermatological diseases | Termination of an agreement |
| 2012-06-08 | GSK (UK) University of Dundee (UK) | new treatments for Recessive Dystrophic Epidermolysis Bullosa (RDEB) | recessive dystrophic epidermolysis bullosa (RDEB) | R&D |
Rare diseases - Genetic diseases - Dermatological diseases | R&D agreement |
| 2012-06-07 | Amorfix Life Sciences (Canada) JSW Lifesciences (Germany) | Amorfix Aggregated Abeta Assay [the A4] (preclinical Alzheimer’s disease diagnostic test) | Alzheimer's disease | licensing |
Neurodegenerative diseases | Licensing agreement |
| 2012-06-06 | Merck KGaA, Merck Serono (Germany) Dr Reddy's (India) | biosimilar compounds in oncoloy (mainly monoclonal antibodies) | cancers | co-development |
Cancer - Oncology | Development agreement |
| 2012-06-04 | Genmab (Denmark) Novartis (Switerland) | DuoBody™ technology platform | R&D |
R&D agreement | ||
| 2012-06-04 | Savira pharmaceuticals (Austria) Roche (Switzerland) | small molecule polymerase inhibitors for the treatment of influenza virus infections | influenza virus infections | collaboration |
Infectious diseases | Licensing agreement |
| 2012-06-02 | GE Healthcare (USA) Affibody (Sweden) | Her2-targeted PET imaging agent | breast cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2012-05-31 | Ventana Medical Systems (USA), a member of the Roche Group (Switzerland) German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) (Germany) University Hospital Heidelberg (Germany) | immunohistochemistry (IHC) primary antibody to detect the V600E BRAF mutation protein | various cancers | licensing |
Cancer - Oncology | Licensing agreement |
| 2012-05-30 | Genmab (Denmark) Cormorant Pharmaceuticals (Sweden) | HuMax-IL8 | cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2012-05-30 | Bayer (Germany) Covance (USA) | R&D services related to Phase II-IV clinical studies and central laboratory services | R&D |
Services contract | ||
| 2012-05-30 | IFP Energies nouvelles (IFPEN) (France) QUIDD (France) | automated processing and analysis of 2D and 3D images | R&D |
R&D agreement | ||
| 2012-05-30 | Galapagos's UK subsidiary BioFocus (Belgium) Ono Pharmaceutical (Japan) | novel targets in the field of allergic diseases | novel targets in the field of allergic diseases including atopic dermatitis and bronchial asthma | R&D |
Respiratory diseases - Inflammatory diseases - Allergic diseases - Dermatological diseases | R&D agreement |
| 2012-05-25 | Biocartis (Belgium) Wellcome Trust Sanger Institute (UK) Philips Research (The Netherlands) | workflow for extraction and amplification & detection of tumor DNA | R&D |
Cancer - Oncology | R&D agreement | |
| 2012-05-24 | Almirall (Spain) ASLAN Pharmaceuticals (Singapore) | LAS186323 | rheumatoid arthritis | R&D |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | R&D agreement |
| 2012-05-23 | Immune Pharmaceuticals (Israel-USA) Yeda Research and Development Company (commercial arm of the Weizmann Institute of Science - Israel) | antibody therapeutics targeting HER3 (HER3 belongs to the epidermal growth factor family which includes HER2 target of Herceptin® (Genentech/ Roche) and EGFR1 target of Erbitux® (Eli Lilly and Merck Serono). HER3 is over expressed in certain patient populations with gastric, head and neck, ovarian and breast cancers.) | collaboration |
Cancer - Oncology | R&D agreement |
